Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions

Future Oncology

Volumn 14, Issue 10, 2018, Pages 907-917

  Handy, Catherine E ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biomarkers; cancer vaccine; castration resistant prostate cancer; immunotherapy; prostate cancer; sipuleucel T

Indexed keywords

ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ATEZOLIZUMAB; BEVACIZUMAB; DNA VACCINE; DOCETAXEL; ENZALUTAMIDE; INDOXIMOD; INTERLEUKIN 7; IPILIMUMAB; NIVOLUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ACID PHOSPHATASE; ANTINEOPLASTIC AGENT; CANCER VACCINE; TISSUE EXTRACT; TUMOR MARKER;

ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; BACKACHE; BIOCHEMICAL RECURRENCE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL STUDY; DENDRITIC CELL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; LIMB PAIN; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CLINICAL TRIAL (TOPIC); LEGISLATION AND JURISPRUDENCE; MALE; MULTIMODALITY CANCER THERAPY; TRENDS;

ACID PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TISSUE EXTRACTS;

EID: 85045473271     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0531     Document Type: Article

References (71)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7-30 (2017).
2. Surveillance Epidemiology and End Results Program. Cancer statistics (2017). www.cancer.gov/about-cancer/understanding/statistics
3. Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med. 5(1), 136-141 (2016).
4. Hamdy FC, Donovan JL, Lane JA et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375(15), 1415-1424 (2016).
5. Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 68(3), 593-598 (2006).
6. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J. Urol. 172(3), 910-914 (2004).
7. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. HO 11(1), 14-23 (2013).
8. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737-746 (2015).
9. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13(10), 983-992 (2012).
10. National Cancer Institute. Drugs approved for prostate cancer (2014). www.cancer.gov/about-cancer/treatment/drugs/prostate
11. Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Curr. Treat. OptionsOncol. 17(12), 64 (2016).
12. Malarkey MA, Witten CM. Approval letter - Provenge (2015). www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm
13. Nair-Gupta P, Blander JM. An updated view of the intracellular mechanisms regulating cross-presentation. Front. Immunol. 4, 401 (2013).
14. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137(5), 1142-1162 (1973).
15. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24(3), 605-610 (1994).
16. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphas. Tumor Immunol. 18(2), 86-94 (1995).
17. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1(12), 1297-1302 (1995).
18. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183(1), 283-287 (1996).
19. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93(20), 10972-10977 (1996).
20. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
21. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2(1), 52-58 (1996).
22. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93(7), 2411-2419 (1999).
23. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998).
24. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5(6), 1331-1338 (1999).
25. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 28(3), 485-495 (1936).
26. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 236(2), 229-238 (2006).
27. Muniyan S, Chaturvedi NK, Dwyer JG, Lagrange CA, Chaney WG, Lin MF. Human prostatic acid phosphatase: structure, function and regulation. Int. J. Mol. Sci. 14(5), 10438-10464 (2013).
28. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 36(2), 129-138 (1998).
29. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18(23), 3894-3903 (2000).
30. Van Voorhis W, Hair LS, Steinman RM, Kaplan G. Human dendritic cells. Enrichment and characterization from peripheral blood. J. Exp. Med. 155(4), 1172-1187 (1982).
31. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).
32. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006).
33. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
34. George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG. Survival outcomes of sipuleucel-T Phase III studies: impact of control-arm cross-over to salvage immunotherapy. Cancer Immunol. Res. 3(9), 1063-1069 (2015).
35. Fong L, Carroll P, Weinberg V et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl Cancer Inst. 106(11), pii:dju268 (2014).
36. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. 10(8), 580-593 (2010).
37. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer 4(1), 55-60 (2005).
38. Beer TM, Bernstein GT, Corman JM et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 17(13), 4558-4567 (2011).
39. Antonarakis ES, Kibel AS, Yu EY et al. Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a Phase II randomized trial. Clin. Cancer Res. 23(10), 2451-2459 (2017).
40. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627-1639 (2015).
41. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med. 363(8), 711-723 (2010).
42. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
43. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15(9), 969-975 (2010).
44. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized Phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. CII 62(1), 137-147 (2013).
45. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013).
46. GuhaThakurta D, Sheikh NA, Fan LQ et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin. Cancer Res. 21(16), 3619-3630 (2015).
47. Drake CG. The potential role of antigen spread in immunotherapy for prostate cancer. Clin. Adv. Hematol. Oncol. 12(5), 332-334 (2014).
48. Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9(7), 513-514 (2010).
49. Hall SJ, Klotz L, Pantuck AJ et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J. Urol. 186(3), 877-881 (2011).
50. Clinical trails database: NCT01306890. https://clinicaltrials.gov/ct2/show/NCT01306890
51. Beer TM, Kwon ED, Drake CG et al. Randomized, double-blind, Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35(1), 40-47 (2017).
52. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700-712 (2014).
53. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
54. Graff JN, Alumkal JJ, Drake CG et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7(33), 52810-52817 (2016).
55. Boudadi K, Suzman DL, Luber B et al. Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). J. Clin. Oncol. 35(15 Suppl.), 5035-5035 (2017).
56. Schweizer MT, Cheng HH, Tretiakova MS et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7(50), 82504-82510 (2016).
57. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415-421 (2013).
58. Le DT, Durham JN, Smith KN et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409-413 (2017).
59. Guedes LB, Antonarakis ES, Schweizer MT et al. MSH2 loss in primary prostate cancer. Clin. Cancer Res. 23(22), 6863-6874 (2017).
60. Gao J, Ward JF, Pettaway CA et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23(5), nm.4308 (2017).
61. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107(1), 67-74 (2006).
62. Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30(13), 1534-1540 (2012).
63. Small EJ, Lance RS, Gardner TA et al. A randomized Phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 21(17), 3862-3869 (2015).
64. Quinn DI, Petrylak DP, Pieczonka CM et al. A randomized Phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). JCO 32(15), e16071-e16071 (2014).
65. Food and Drug Administration. FDA approval for ipilimumab (2011). www.accessdata.fda.gov/drugsatfda docs/label/2011/125377s0000lbl.pdf
66. Scholz M, Yep S, Chancey M et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther. 6, 11-16 (2017).
67. European Medicines Agency. Provenge. Press Release (2013). www.ema.europa.eu/docs/en GB/document library/EPAR - Summary for the public/human/002513/WC500151157.pdf
68. European Medicines Agency. Provenge (2015). www.ema.europa.eu/ema
69. Sanpower Group. Sanpower Group completes the acquisition of Dendreon from Valeant. PRNewswire (2017). www.prnewswire.com/news-releases/sanpower-group-completes-the-acquisition-of -dendreon-from-valeant-300481852.html
70. Integrated analysis - ∗Two simultaneous trials of 225 men with mCRPC demonstrating overall survival benefit compared to placebo.
71. IMPACT trial - ∗Pivotal randomized Phase III trial of 127 men with mCRPC demonstrating overall survival benefit compared to placebo.